SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock Holdings Increased by Swiss National Bank

Swiss National Bank lifted its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 7.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 116,800 shares of the company’s stock after purchasing an additional 8,000 shares during the quarter. Swiss National Bank owned 0.16% of SpringWorks Therapeutics worth $4,220,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. AlphaQuest LLC grew its position in SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after buying an additional 414 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of SpringWorks Therapeutics in the 4th quarter worth approximately $10,527,000. Arizona State Retirement System boosted its holdings in shares of SpringWorks Therapeutics by 7.5% in the fourth quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock valued at $622,000 after acquiring an additional 1,206 shares in the last quarter. M&T Bank Corp increased its stake in shares of SpringWorks Therapeutics by 16.0% during the fourth quarter. M&T Bank Corp now owns 20,155 shares of the company’s stock valued at $728,000 after acquiring an additional 2,774 shares during the period. Finally, Assetmark Inc. raised its holdings in SpringWorks Therapeutics by 4.8% during the fourth quarter. Assetmark Inc. now owns 48,216 shares of the company’s stock worth $1,742,000 after purchasing an additional 2,196 shares in the last quarter.

SpringWorks Therapeutics Stock Down 2.7 %

Shares of NASDAQ SWTX opened at $47.21 on Wednesday. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -13.57 and a beta of 0.76. The business has a fifty day simple moving average of $47.22 and a 200-day simple moving average of $39.58.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $61.55 million for the quarter, compared to analysts’ expectations of $60.53 million. As a group, sell-side analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, CEO Saqib Islam sold 48,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the sale, the chief executive officer now owns 1,002,502 shares in the company, valued at $53,433,356.60. This represents a 4.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel Pichl sold 29,750 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the transaction, the insider now owns 50,762 shares in the company, valued at approximately $2,759,422.32. This represents a 36.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 440,766 shares of company stock worth $24,402,956. Corporate insiders own 7.61% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SWTX shares. Evercore ISI lifted their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Wedbush reissued an “outperform” rating and issued a $81.00 price target on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Finally, Guggenheim lowered their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $73.20.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.